MON-733 - 3-Month Real-World Weight-Related Outcomes Among Patients Taking Oral Semaglutide 25 mg: Insights From the WeGoTogether Patient Support Solution App

Introduction:
Oral semaglutide 25 mg was approved by the U.S. Food and Drug Administration in December 2025 for weight management in adults with overweight or obesity based on results from the OASIS 4 clinical trial. However, evidence on its real-world effectiveness remains limited. WeGoTogether (WGT) is a patient support application available in the United States, designed to help individuals treated with semaglutide by providing education on pharmacotherapy for weight management, one-on-one health coaching, and tools to track treatment progress. This study aimed to describe the baseline characteristics of early adopters of oral semaglutide 25 mg enrolled in WGT, and to assess short-term weight-related outcomes among individuals naïve to weight-loss medication.

Methods:
This was a single-arm retrospective cohort study that included de-identified data from adults with overweight or obesity (body mass index (BMI) ≥ 25 kg/m2) enrolled in WGT who initiated oral semaglutide on or after January 5 and before April 13, 2026. Patients were indexed on the date of the first logged dose. Baseline demographics (age range, sex, and region) and clinical characteristics (weight, BMI, waist circumference [WC] and starting dose) were summarized descriptively. Changes in weight-related outcomes (weight, BMI, WC) from baseline (Day 0 ± 7) to 3 months (Day 84 ± 7) were assessed among individuals new to weight-loss medications with measurements recorded at both timepoints. Outcomes were compared using a paired t-test. All data were self-reported.

Results:
Among 9,555 patients who initiated oral semaglutide 25 mg for weight management during the study period, most were aged 41-60 (55.3%), 84.4% were women and the majority were from the South or Northeast (61.4%) of the U.S. Overall, 6,200 (64.9%) reported being new to weight-loss medication. Most patients initiated treatment at the lowest available dose of 1.5 mg (87.8%). At baseline, mean (SD) BMI was 36.0 (6.9) kg/m2 and WC was 105 (18.6) cm; both were similar between sexes. Baseline weight was 116 (22.1) kg in men and 96.7 (19.9) kg in women.
Of the 6,200 individuals naïve to weight-loss medication, 564 initiated treatment by January 25 − early enough to report 3-month follow-up data before end of the study period. At 3 months, patients reported a mean (95% confidence interval) weight change of -6.8% (-7.4, -6.3) (N = 171) and BMI change of -2.4 kg/m2 (-2.6, -2.2) (N = 171). Mean change in WC was -6.6 cm (-7.6, -5.5) or -2.6 in (N = 77).

Conclusions:
In this real-world cohort of individuals using the WGT patient support solution, initiation of oral semaglutide 25 mg was associated with a statistically significant and clinically meaningful weight loss, along with a substantial reduction in waist circumference within the first 3 months of treatment. The observed weight change was comparable to that reported at a similar timepoint in the OASIS 4 clinical trial (-5.3% at 12 weeks).

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*